Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q2 FY2014 Earnings Presentation
18 slides from Torrent Pharmaceuticals's earnings presentation, 2013
Slide 1: Investor Presentation Q2 FY 2013-14
TORRENT PHARMACEUTICALS LTD. Investor Presentation Q2 FY 2013-14
Slide 2: Caveat
Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre
Slide 3: Contents
Contents 1. Performance Highlights 2. Financials 3. Business Segments – India – International 4. Facilities – Expansion Plan
Slide 4: Q2 FY14 Highlights
Q2 FY14 Highlights • Revenues at ` 972 Cr vs. ` 777 Cr, growing at 25%; • India formulation market growing at 10% & • International operations growing at 32%; Constant currency growth of 18% • Europe & ROW markets key contributors to growth of international operations • PBT at ` 152 Cr vs. ` 139 Cr
Slide 5: Financials
Financials Fx orer
Slide 6: Revenue Progression
Revenue Progression ` Cr Q2 Q2 Particulars 12-13 11-12 13 - 14 12 - 13 India 297 271 1,024 909 Gwth % 10% 13% International 573 435 1,834 1,482 Gwth % 32% 24% Brazil 125 116 502 477 Europe 235 152 650 542 USA 115 93 355 216 ROW * 97 74 327 247 Contract Manufacturing 100 67 300 296 Gwth % 49% 1% Othe
Slide 7: P&L
P&L ` Cr Q2 Q2 Particulars 12-13 11-12 13 - 14 12 - 13 Revenues 972 777 3,212 2,696 COGS 301 217 926 863 % Revenues 31% 28% 29% 32% SG&A Spend 274 237 965 778 % Revenues 28% 31% 30% 29% Employee Cost 182 155 623 534 % Revenues 19% 20% 19% 20% EBITDA 215 168 698 522 % Revenues 22% 22% 22% 19% Forex G
Slide 8: Balance Sheet
Balance Sheet ` Cr Particulars 31-Mar-13 % 30-Sep-13 % ∆ EQUITY AND LIABILITIES Shareholders' Funds 1,422 69% 1,501 70% 79 Minority Interest 0 0% 0 0% 0 Non-current liabilities 651 31% 638 30% (13) TOTAL 2,073 100% 2,139 100% 66 ASSETS Net Fixed Assets 1,105 53% 1,276 60% 171 Loans & Advances 63 3%
Slide 9: Business Segments: India
Business Segments India
Slide 10: India: Highlights & Growth Drivers
India Highlights & Growth Drivers ` Cr Q2 Q2 India 12-13 11-12 13 - 14 12 - 13 Revenues 297 271 1024 909 % Growth 10% 13% 9% • Q2 FY 14 Highlights • IPM growth: 2.8%, Covered Market growth: 3.1%, Torrent growth: 11.9% • Q2 was impacted mainly due to disruption in Trade because of NLEM. • Situation t
Slide 11: Business Segments: International Operations
Business Segments International Operations
Slide 12: Brazil: Highlights & Growth Drivers
Brazil Highlights & Growth Drivers ` Cr Q2 Q2 Brazil 12-13 11-12 13 - 14 12 - 13 Revenues 125 116 502 477 % Growth 8% 5% 34% • Q2 FY 14 Highlights • Constant currency growth at 8%. • Covered Market Growth (excluding Government reimbursement programme) is 10%, Torrent growth 8% as per IMS. • Price re
Slide 13: USA: Highlights & Growth Drivers
USA Highlights & Growth Drivers ` Cr Q2 Q2 USA 12-13 11-12 13 - 14 12 - 13 Revenues 115 93 355 216 % Growth 24% 64% 89% • Q2 FY 14 Highlights • Constant currency growth 10% • During PY company received one time licensing income of Rs 11 cr. Adjusting for which growth is 40%, Constant currency growth
Slide 14: Europe: Highlights & Growth Drivers
Europe Highlights & Growth Drivers ` Cr Q2 Q2 Europe 12-13 11-12 13 - 14 12 - 13 Revenues 235 152 650 542 % Growth 54% 20% 16% • Q2 FY 14 Highlights • Euro revenue growth – 31% • Heumann, Europe (Dossier Business) & UK contributors to growth • Growth Drivers • New Products going off patent and Thera
Slide 15: ROW: Highlights & Growth Drivers
ROW Highlights & Growth Drivers ` Cr Q2 Q2 ROW 12-13 11-12 13 - 14 12 - 13 Revenues 97 74 327 247 % Growth 31% 91% 16% • Q2 FY14 Highlights • Revenue growth of 15% on constant currency basis. • Growth Drivers • Middle East/ Africa Region Delivering the growth being an upcoming market • Continuous re
Slide 16: Facilities - Expansion Plan
Facilities - Expansion Plan Fx orer
Slide 17: Facilities – Expansion Plan: Dahej SEZ
Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1100 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 750 crores, First Regulatory Approval: Q2’14-15 • Pha
Slide 18: Thank You
Thank You Fx orer
Torrent Pharmaceuticals — Q2 FY2014 Earnings Presentation on 6ix